East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deferasirox Tablets, 90 mg, 180 mg, and 360 mg. Aurobindo Pharma’s Deferasirox Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Jadenu® Tablets manufactured by Novartis Pharmaceuticals Corporation.

Deferasirox Tablets are indicated for:

• The treatment of chronic iron overload due to blood transfusions (transfusional iron overload)
• The treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes.